Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3

Cell

Volumn 85, Issue 5, 1996, Pages 683-693

  Brooks, Peter C ^a   Strömblad, Staffan ^a   Sanders, Luraynne C ^a   Von Schalscha, Tami L ^a   Aimes, Ronald T ^b   Stetler Stevenson, William G ^c   Quigley, James P ^b   Cheresh, David A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; COLLAGENASE; INTEGRIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; COVALENT BOND; ENZYME ACTIVATION; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALIA;

EID: 15844420283     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81235-0     Document Type: Article

References (59)

1. Aimes, R.T., French, D.L., and Quigley, J.P. (1994). Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using genefamilyPCR: expression of gelatinase increase upon malignant transformation. Biochem. J. 300, 729-736.
2. Albelda, S.M. (1993). Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 68, 4-17.
3. Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., and Buck, C.A. (1990). Integrin distribution in malignant melanoma: association of β3 subunit with tumor progression. Cancer Res. 50, 6757-6764.
4. Birkedal-Hansen, H. (1995). Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7, 728-735.
5. Blasi, F. (1993). Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasion. Bioessays 15, 105-111.
6. Blood, C.H., and Zetter, B.R. (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032, 89-118.
7. Brooks, P.C., Lin, J.-M., French, D.L., and Quigley, J.P. (1993). Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis. J. Cell Biol. 122, 1351-1359.
8. Brooks, P.C., Clark, R.A.F., and Cheresh, D.A. (1994a). Requirement of integrin αvβ3 for angiogenesis. Science 264, 569-571.
9. Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., and Cheresh, D.A. (1994b). Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
10. Brooks, P.C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F.H., and Cheresh, D.A. (1995). Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822.
11. r 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50, 6184-6191.
12. Cao, J., Sato, H., Takino, T., and Seiki, M. (1995). The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for progelatinase A activation. J. Biol Chem. 270, 801-805.
13. Chen, J.-M., Aimes, R.T., Ward, G.R., Youngleib, G.L., and Quigley, J.P. (1991). Isolation and characterization of a 70 kDa metalloprotease (gelatinase) that is elevated in Rous sarcoma virus-transformed chicken embryo fibroblasts. J. Biol. Chem. 266, 5113-5121.
14. Crowley, C.W., Cohen, R.L., Lucas, B.K., Liu, G., Shuman, M.A., and Levinson, A.D. (1993). Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 90, 5021-5025.
15. Davis, G.E. (1992). Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun. 182, 1025-1031.
16. r 72,000 type IV collagenase. Cancer Res. 52, 5845-5848.
17. Felding-Habermann, B., and Cheresh, D.A. (1993). Vitronectin and its receptor. Curr. Opin. Cell Biol. 5, 864-868.
18. Filardo, E.J., Brooks, P.C., Deming, S.L., Damsky, C., and Cheresh, D.A. (1995). Requirement of the NPXY motif in the integrin β3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. Cell Biol. 130, 441-450.
19. Filardo, E.J., Deming, S.L., and Cheresh, D.A. (1996). Regulation of cell migration by the integrin β subunit ectodomain. J. Cell Sci., in press.
20. Frelinger, A.L., Cohen, I., III, Plow, E.A., Smith, M.A., Roberts, J., Lam, S.C.-T., and Ginsberg, M.H. (1990). Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. 265, 6346-6352.
21. Friedlander, M., Brooks, P.C., Shatter, R.W., Kincaid, C.M., Varner, J.A., and Cheresh, D.A. (1995). Definition of two angiogenic pathways by distinct av integrins. Science 270, 1500-1502.
22. Gladson, C.L., and Cheresh, D.A. (1991). Glioblastoma expression of vitronectin and the αvβ3 integrin. J. Clin. Invest. 88, 1924-1932.
23. Grevin, D., Chen, J.H., Raes, M.-B., Stehelin, D., Vandenbunder, B., and Desbiens, X. (1993). Involvement of the proto-oncogene c-ets 1 and the urokinase plasminogen activator during mouse implantation and placentation. Int. J. Dev. Biol. 37, 519-529.
24. Hynes, R.O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
25. Kleiner, D.E., Tuuttila, A., Tryggvason, K., and Stetler-Stevenson, W.G. (1993). Stability analysis of latent and active 72 kDa type IV collagenase: the role of tissue inhibitor of metalloproteinase-2 (TIMP-2). Biochemistry 32, 1583-1592.
26. Kleiner, D.E., and Stetler-Stevenson, W.G. (1993). Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell Biol. 5, 891-897.
27. Knudsen, K.A., Damsky, C.H., and Buck, C.A. (1982). Expression of adhesion-related membrane components in adherent versus nonadherent melanoma cells. J. Cell. Biochem. 18, 157-167.
28. Kook, Y.H., Adamski, J., Zelent, A., and Ossowski, L. (1994). The effects of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13, 3983-3991.
29. Lester, B.R., and McCarthy, J.B. (1992). Tumor cell adhesion to the extracellular matrix and signal transduction mechanisms implicated in tumor cell motility, invasion, and metastasis. Cancer Metastasis Rev. 11, 31-44.
30. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
31. Mignatti, P., and Rifkin, D.B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195.
32. r 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 53, 3159-3164.
33. Montgomery, A.M.P., Reisfeld, R.A., and Cheresh, D.A. (1994). Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA 91, 8856-8860.
34. Montgomery, A.M.P., De Clerk, Y.A., Langley, K.E., Reisfeld, R.A., and Mueller, B.M. (1993). Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 53, 693-700.
35. Moses, M.A., Sudhalter, J., and Langer, R. (1990). Identification of an inhibitor of neovascularization from cartilage. Nature 248, 1408-1410.
36. Moses, M.A., and Langer, R. (1991). A metalloproteinase inhibitor as an inhibitor of neovascularization. J. Cell. Biochem. 47, 230-235.
37. Mueller, S.C., and Chen, W.-T. (1991). Cellular invasion into matrix beads: localization of β1 integrins and fibronectin to the invadopodia. J. Cell Sci. 99, 213-225.
38. Murphy, I., Willenbrock, F., Ward, R.V., Cockett, M.I., Eaton, D., Andrew, R., and Docherty, J.P. (1992). The C-terminal domain of 72 kDa gelatinase A is not required for catalysis but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. J. Biochem. 283, 637-641.
39. Nakajima, I.A., Sasaguri, S., Nagase, H., and Mori, Y. (1995). Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhance the production of matrix metalloproteinases 1, 2, and 3 in fibroblasts. Br. J. Cancer 71, 1039-1045.
40. Newman, P.J., Allen, R.W., Kahn, R.A., and Kunicki, T.J. (1985). Quantitation of membrane glycoprotein Ilia on intact human platelets using the monoclonal antibody AP3. Blood 65, 227-232.
41. Orlando, R.A., and Cheresh, D.A. (1991). Arginine-glycine-aspartic acid binding to molecular stabilization between integrin αvβ3 and its ligand. J. Biol. Chem. 266, 19543-19555.
42. Pepper, M.S., Vassalli, J.-D., Wilks, J.W., Schweigerer, L., Orci, L., and Montesano, R. (1994). Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell. Biochem. 55, 419-434.
43. Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R., and Engel, J. (1994). Selective recognition of cyclic RGD peptides of NMR-defined conformation by αIIb β3, αvβ3, and α5β1 integrins. J. Biol. Chem. 269, 20233-20238.
44. Reinartz, J., Schafer, B., Batrla, R., Klein, C.E., and Kramer, M.D. (1995). Plasmin abrogates αvβ5-mediated adhesion of a human keratinocyte line (HaCat). Exp. Cell Res. 214, 486-498.
45. Rucklidge, G.J., Edvardsen, K., and Bock, E. (1994). Cell-adhesion molecules and metalloproteinases: a linked role in tumor cell invasiveness. Biochem. Soc. Trans. 22, 63-68.
46. Ruoslahti, E. (1992). Control of cell motility and tumor invasion by extracellular matrix interactions. Br. J. Cancer. 66, 239-242.
47. Ruoslahti, E., and Giancotti, F.G. (1989). Integrins and tumor cell dissemination. Cancer Cells 1, 119-126.
48. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994). A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370, 61-65.
49. Smith, J.W., and Cheresh, D.A. (1988). The Arg-Gly-Asp binding domain of the vitronectin receptor. J. Biol. Chem. 263, 18726-18731.
50. Smith, J.W., Vestal, D.J., Irwin, S.V., Burke, T.A., and Cheresh, D.A. (1990). Purification and functional characterization of integrin αvbeta;5. J. Biol. Chem. 265, 11008-11013.
51. Stetler-Stevenson, W.G., Aznavoorian, S., and Liotta, L.A. (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9, 541-573.
52. Strongin, A.Y., Marmer, B.L., Grant, G.A., and Goldberg, G.I. (1993). Plasma membrane-dependent activation of the 72 kDa type IV collagenase is prevented by complex formation with TIMP-2. J. Biol. Chem. 268, 14033-14039.
53. Strongin, A.Y., Collier, I., Bannikov, G., Marmer, B.L., Grant, G.A., and Goldberg, G.I. (1995). Mechanism of cell surface activation of 72 kDa type IV collagenase. J. Biol. Chem. 270, 5331-5338.
54. Thomas, L., Chan, P.W., Chan, S., and Damsky, C. (1993). 5-bromo-2 deoxyuridine regulates invasiveness and expression of integrins and matrix-degrading proteinases in a differentiated hamster melanoma cell. J. Cell Sci. 105, 191-201.
55. Ward, R.V., Atkinson, S.J., Slocombe, P.M., Docherty, A.J.P., Reynolds, J.J., and Murphy, G. (1991). Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim. Biophys. Acta 707, 242-246.
56. Wayner, E.A., Orlando, R.A., and Cheresh, D.A. (1991). Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113, 919-929.
57. Wolfsberg, T.G., Bazan, J.F., Blobel, C.P., Myles, D.G., Primakoff, P., and White, J.M. (1993). The precursor region of a protein active in sperm-egg fusion contains a metalloproteinase and a disintegrin domain: structural, functional, and evolutionary implications. Proc. Natl. Acad. Sci. USA 90, 10783-10787.
58. Wolfsberg, T.G., Primakoff, P., Myles, D.G., and White, J.M. (1995). ADAM, a novel family of membrane proteins containing adisintegrin and metalloproteinase domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 131, 275-278.
59. Yan, H.-C., Juhasz, I., Pilewski, J., Murphy, G.F., Herlyn, M., and Albelda, S.M. (1993). Human/severe combined immunodeficient mouse chimeras. J. Clin. Invest. 91, 986-996.